JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

Search

Merck & Co Inc.

Suletud

SektorTervishoid

87.59 -0.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

87

Max

88.73

Põhinäitajad

By Trading Economics

Sissetulek

-656M

4.4B

Müük

277M

16B

P/E

Sektori keskmine

13.079

37.461

Aktsiakasum

2.13

Dividenditootlus

3.73

Kasumimarginaal

28.021

Töötajad

73,000

EBITDA

-892M

6.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+8.8% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.73%

2.33%

Järgmine tulemuste avaldamine

30. okt 2025

Turustatistika

By TradingEconomics

Turukapital

4.5B

216B

Eelmine avamishind

87.64

Eelmine sulgemishind

87.59

Uudiste sentiment

By Acuity

37%

63%

127 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. okt 2025, 12:19 UTC

Suurimad hinnamuutused turgudel

Bicara Shares Rise Premarket on FDA Breakthrough Designation

11. aug 2025, 12:43 UTC

Suurimad hinnamuutused turgudel

IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data

29. juuli 2025, 10:45 UTC

Tulu

Merck & Co. to Lay Off Workers, Reduce Real Estate to Invest in New Products

7. okt 2025, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Merck Completes Acquisition Of Verona Pharma >MRK VRNA

29. juuli 2025, 11:13 UTC

Tulu

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29. juuli 2025, 10:45 UTC

Tulu

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29. juuli 2025, 10:30 UTC

Tulu

Merck: Updated FY Adj EPS Outlook Does Not Include Anticipated Impact of Verona Pharma Acquisition >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: $200M of Costs Related to Impact of Tariffs in FY Outlook Unchanged Vs Previous Guidance Pending Outcome of Additional Potential Government Actions >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: As Part of Initiative, Approved New Restructuring Program in Which Co. Expects to Eliminate Certain Administrative, Sales and R&D Positions >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Updated FY Adj EPS Outlook Includes Revised Negative Impact of Foreign Exchange of About 15c/Shr >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: For Latest 2Q, Recorded Charges of $649M Related to Restructuring Program >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck Narrows FY View To Sales $64.3B-$65.3B Vs Prior View $64.1B-$65.6B >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Expect Actions Under Restructuring Program to Result in Annual Cost Savings of About $1.7B, Which Will Be Substantially Realized by End of 2027 >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Will Continue to Hire Employees Into New Roles Across Strategic Growth Areas of the Business >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Restructuring Program Is Part of the Multiyear Optimization Initiative Expected to Achieve $3B in Annual Cost Savings by End of 2027 >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck Sees Cumulative Pretax Costs Related to Program to Be About $3B >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck Launching New Multiyear Optimization Initiative to Enable Transformation of CO's Portfolio by Generating Expected $3B in Annual Cost Savings From Productivity Actions >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Savings Will Be Fully Reinvested to Support New Product Launches and Pipeline Across Multiple Therapeutic Areas >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Will Reduce Global Real-Estate Footprint and Continue to Optimize Manufacturing Network, Aligning Geography of Global Manufacturing to Co's Customers >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Winrevair Sales $336M >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Keytruda Sales Up 9% >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Lower Gardasil/Gardasil 9 and Januvia/Janumet Sales Primarily Due to Lower Demand in China >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Gardasil/Gardasil 9 Sales Down 55% >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Gardasil/Gardasil 9 Sales $1.13B >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Animal Health Sales Up 11% >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Pharmaceutical Sales Down 2% >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Januvia/Janumet Sales Down 1% >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Sales $15.81B >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Pharmaceutical Sales $14.05B >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck 2Q Animal Health Sales $1.65B >MRK

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

8.8% tõus

12 kuu keskmine prognoos

Keskmine 95.33 USD  8.8%

Kõrge 120 USD

Madal 82 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

4

Osta

8

Hoia

0

Müü

Tehniline skoor

By Trading Central

76.03 / 83.28Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

127 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat